Skip to main content
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.
Published Web Location
http://europepmc.org/articles/PMC4396529?pdf=renderNo data is associated with this publication.
Abstract
To assess the safety, tolerability, and preliminary efficacy of NP001, a novel immune regulator of inflammatory monocytes/macrophages, for slowing progression of amyotrophic lateral sclerosis (ALS).This was a phase 2 randomized, double-blind, placebo-contr
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.